SunTrust Downgrades Glycomimetics (GLYC) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Glycomimetics (GLYC) PT Lowered to $18 at H.C. Wainwright
August 5, 2019 7:23 AM EDTH.C. Wainwright analyst Edward White lowered the price target on Glycomimetics (NASDAQ: GLYC) to $18.00 (from $23.00) while maintaining a Buy rating.
... MoreGlycoMimetics (GLYC) Announces Pfizer's (PFE) Phase 3 Clinical Trial Evaluating Rivipansel in SCD Did Not Meet Endpoints (Earlier)
August 5, 2019 6:18 AM EDTGlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating... More
Glycomimetics (GLYC) PT Lowered to $14 at Stifel
August 5, 2019 2:57 AM EDTStifel analyst Stephen Willey lowered the price target on Glycomimetics (NASDAQ: GLYC) to $14.00 (from $21.00) while maintaining a Buy rating.
... MorePiper Jaffray Downgrades Glycomimetics (GLYC) to Neutral
August 5, 2019 2:56 AM EDTPiper Jaffray analyst Danielle Brill downgraded Glycomimetics (NASDAQ: GLYC) from Overweight to Neutral with a price target of $6.00 (from $20.00).
For an analyst ratings summary and ratings history on Glycomimetics click here. For more ratings news on Glycomimetics click here.
Shares of Glycomimetics closed at $6.00 yesterday.
... More